Completed PHASE3 INTERVENTIONAL NCT00094991

Mechanism of Action and Efficacy of Muraglitazar in Type 2 Diabetes

Mechanism of Action and Efficacy of Muraglitazar (BMS298585) in the Treatment of Type 2 Diabetic Patients

Sponsor: Bristol-Myers Squibb

Updated 7 times since 2017 Last updated: Sep 10, 2010 Started: May 31, 2004 Primary completion: May 31, 2006 Completion: May 31, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00094991, this PHASE3 trial focuses on Diabetes Mellitus, Type 2 and remains completed. Sponsored by Bristol-Myers Squibb, it has been updated 7 times since 2004, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jun 2022 — Jul 2024 [monthly]

Completed PHASE3
Apr 2022 — Jun 2022 [monthly]

Completed PHASE3
Jan 2021 — Apr 2022 [monthly]

Completed PHASE3

▶ Show 2 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

May 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Bristol-Myers Squibb
Merck Sharp & Dohme LLC

Data source: Bristol-Myers Squibb

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Pisa, Italy
• San Antonio, United States